YS Biopharma Co. Ltd. (YS)
1.02
0.09 (9.68%)
At close: May 24, 2024, 8:00 PM
1.07
4.90%
After-hours: May 24, 2024, 07:20 PM EDT
Company Description
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles.
It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.
The company was founded in 2002 and is based in Beijing, China.
YS Biopharma Co. Ltd.
| Country | CN |
| IPO Date | Aug 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 773 |
| CEO | Dr. Hui Shao C.F.A., M.B.A., Ph.D. |
Contact Details
Address: Building No. 2 Beijing, CN | |
| Website | https://www.yishengbio.com |
Stock Details
| Ticker Symbol | YS |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001946399 |
| CUSIP Number | n/a |
| ISIN Number | KYG9845F1090 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dave Chenn | Co-Chief Executive Officer |
| Dr. Hui Shao C.F.A., M.B.A., Ph.D. | Co-Chief Executive Officer, President, Chief Business Officer & Executive Director |
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
| Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer |
| Gang Li | Head of Marketing & Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 6-K | Filing |
| Mar 14, 2025 | S-8 POS | Filing |
| Mar 12, 2025 | 6-K | Filing |
| Dec 19, 2024 | 6-K | Filing |
| Dec 12, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Nov 07, 2024 | 6-K | Filing |
| Nov 01, 2024 | 6-K | Filing |
| Oct 29, 2024 | 6-K | Filing |
| Oct 25, 2024 | 6-K | Filing |